Alecta Optimizes Cross-Asset Trading and Execution with FlexTRADER EMS
Alecta will use FlexTrade’s flagship EMS to handle equities and derivatives execution.
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Alecta, the fifth-biggest occupational pension company in Europe, today announced that Alecta is live and in production using FlexTRADER EMS for equities and derivatives trading.
Stockholm-based Alecta decided to replace its existing EMS solution to support the efficient growth of its equities and derivatives trading activities. The new solution selected would need to deliver the ability to trade cross-asset, offer innovative new functionality, and connect seamlessly to Alecta’s existing order management tool, Order Manager, a key component of financial technology company SimCorp’s front-to-back integrated platform, SimCorp One. Alecta thoroughly evaluated solutions in the market and opted to deploy FlexTrade’s multi-asset execution management solution, FlexTRADER EMS.
Following the successful implementation of FlexTRADER EMS, which was completed in under three months, Alecta’s trading team now benefits from an advanced equities and derivatives trading platform that will handle the execution of both asset classes from a single order blotter. As part of the implementation, Alecta has also deployed innovative, bespoke functionality created by FlexTrade’s Client Services team.
Further, FlexTRADER EMS’s open-architecture design, robust APIs, and ability to handle vast volumes of data has enabled Alecta to integrate innovative sources of pre-trade data, such as Kepler Cheuvreux’s KCx API Analytical Suite, directly into the FlexTrade order blotter to help optimize trading decision-making. Following the project's go-live, Alecta has also benefited from increased efficiency via a seamless integration between their existing OMS provider, SimCorp, and FlexTRADER EMS, developed through FlexTrade’s participation as a partner in SimCorp’s Open Platform ecosystem.
Göran Wall, Trader at Alecta:“We’re delighted to have deployed FlexTRADER EMS as our new execution management system for our trading desk. Our requirements were two-fold. We wanted to deploy a sophisticated solution that could help us optimize pre-trade decision-making and efficiently meet our best-execution obligations on the desk. We also wanted to work with a vendor who could collaborate with and seamlessly integrate their solution into our existing OMS provider, SimCorp. We have achieved this, on both criteria, with our decision to select FlexTRADER EMS.”
Dan Enstedt, VP – Business Development and Sales, EMEA, stated:"We warmly welcome Alecta as the latest FlexTRADER EMS client, who is live and in production via our partnership with SimCorp. A commonly requested feature of any EMS implementation is improving the connectivity between the OMS and EMS to enable interoperable, shared workflows and consistent data flow between the applications. Through our formal OMS partnerships, including SimCorp, we can offer a collaborative approach that delivers value to the client. It provides a faster time to market, with the implementation delivered in under three months, and through a joined-up approach, no matter how intricate the workflow or the bespoke functionality is needed, we can cater 100% to the client."
Anders Kirkeby, Head of Open Innovation at SimCorp, noted: “SimCorp’s partner ecosystem isdesigned to offer our clients, like Alecta, easy access to a broad range of complementary solutions across the investment value chain to meet their specific needs. This approach delivers value to SimCorp’s clients by providing a smoother onboarding process and faster time to value for new technology investments, as demonstrated by our successful project with FlexTrade and Alecta.”
About FlexTrade
FlexTrade Systems provides customized multi-asset execution and order management trading solutions for buy- and sell-side financial institutions. Through deep client partnerships with some of the world’s largest, most complex, and demanding capital markets firms, we develop flexible tools, technology, and innovation that deliver our clients a competitive edge. Our globally distributed engineering teams focus on adaptable technology and open architecture to develop highly sophisticated trading solutions that can automate and scale with your business strategies.
About SimCorp
SimCorp is a provider of industry-leading integrated investment management solutions for the global buy side.
Founded in 1971, with more than 3,000 employees across five continents, SimCorp is a truly global technology leader that empowers more than half of the world’s top 100 financial companies through its integrated platform, services, and partner ecosystem.
SimCorp is a subsidiary of Deutsche Börse Group. As of 2024, SimCorp includes Axioma, the leading provider of risk and management and portfolio optimization solutions for the global buy side.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241127759062/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom